6 results on '"Maruno, T."'
Search Results
2. Simultaneous activation of Kras-Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway.
- Author
-
Namikawa M, Fukuda A, Mizukoshi K, Iwane K, Kawai M, Yamakawa G, Omatsu M, Sono M, Masuda T, Araki O, Nagao M, Yoshikawa T, Ogawa S, Hiramatsu Y, Muta Y, Tsuda M, Maruno T, Nakanishi Y, Tsuruyama T, Taura K, Hatano E, and Seno H
- Subjects
- Humans, Mice, Animals, Proto-Oncogene Proteins c-akt, Mechanistic Target of Rapamycin Complex 1, Phosphatidylinositol 3-Kinases, Bile Ducts, Intrahepatic pathology, Biliary Tract Neoplasms, Cholangiocarcinoma pathology, Carcinoma in Situ pathology, Bile Duct Neoplasms pathology
- Abstract
Biliary tract cancer (BTC) has poor prognosis. The Notch receptor is aberrantly expressed in extrahepatic cholangiocarcinoma (eCCA). However, the role of Notch signaling in the initiation and progression of eCCA and gallbladder (GB) cancer remains unknown. Therefore, we investigated the functional role of Notch signaling during tumorigenesis of the extrahepatic bile duct (EHBD) and GB. Activation of Notch signaling and oncogenic Kras resulted in the development of biliary intraepithelial neoplasia (BilINs) in the EHBD and GB, which were premalignant lesions that progressed to adenocarcinoma in mice. The expression of genes involved in the mTORC1 pathway was increased in biliary spheroids from Hnf1b-CreERT2; Kras
LSL-G12D ; Rosa26LSL-NotchIC mice and inhibition of the mTORC1 pathway suppressed spheroid growth. Additionally, simultaneous activation of the PI3K-AKT and Notch pathways in EHBD and GB induced biliary cancer development in mice. Consistent with this, we observed a significant correlation between activated NOTCH1 and phosphorylated Ribosomal Protein S6 (p-S6) expression in human eCCA. Furthermore, inhibition of the mTORC1 pathway suppressed the growth of Notch-activated human biliary cancer cells in vitro and in vivo. Mechanistically, the Kras/Notch-Myc axis activated mTORC1 through TSC2 phosphorylation in mutant biliary spheroids. These data indicate that inhibition of the mTORC1 pathway could be an effective treatment strategy for Notch-activated human eCCA. © 2023 The Pathological Society of Great Britain and Ireland., (© 2023 The Pathological Society of Great Britain and Ireland.)- Published
- 2023
- Full Text
- View/download PDF
3. p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.
- Author
-
Nagao M, Mizukoshi K, Nakayama S, Namikawa M, Hiramatsu Y, Maruno T, Nakanishi Y, Tsuruyama T, Fukuda A, and Seno H
- Subjects
- Animals, Mice, Bile Ducts, Intrahepatic pathology, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, Bile Duct Neoplasms genetics, Bile Duct Neoplasms prevention & control, Bile Duct Neoplasms pathology, Bile Ducts, Extrahepatic pathology, Biliary Tract Neoplasms pathology, Cholangiocarcinoma pathology, Precancerous Conditions genetics, Precancerous Conditions pathology
- Abstract
KRAS and TP53 mutations are frequently observed in extrahepatic biliary cancer. Mutations of KRAS and TP53 are independent risk factors for poor prognosis in biliary cancer. However, the exact role of p53 in the development of extrahepatic biliary cancer remains elusive. In this study, we found that simultaneous activation of Kras and inactivation of p53 induces biliary neoplasms that resemble human biliary intraepithelial neoplasia in the extrahepatic bile duct and intracholecystic papillary-tubular neoplasm in the gall bladder in mice. However, inactivation of p53 was not sufficient for the progression of biliary precancerous lesions into invasive cancer in the context of oncogenic Kras within the observation period. This was also the case in the context of additional activation of the Wnt signaling pathway. Thus, p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.
- Published
- 2023
- Full Text
- View/download PDF
4. Mapping biopsy for bile duct cancer using a novel device delivery system.
- Author
-
Matsumori T, Uza N, Shiokawa M, Maruno T, Kuwada T, Marui S, and Seno H
- Subjects
- Bile Ducts pathology, Bile Ducts, Intrahepatic pathology, Biopsy, Humans, Bile Duct Neoplasms pathology, Cholangiocarcinoma pathology
- Abstract
Competing Interests: The authors declare that they have no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
5. A novel technique for mapping biopsy of bile duct cancer.
- Author
-
Okada H, Uza N, Matsumori T, Matsumoto S, Muramoto Y, Ota S, Nakamura T, Yoshida H, Hirano T, Kuwada T, Marui S, Sogabe Y, Morita T, Kakiuchi N, Mima A, Ueda T, Nishikawa Y, Tsuda M, Maruno T, Shiokawa M, Takahashi K, Taura K, Minamiguchi S, Kodama Y, and Seno H
- Subjects
- Bile Ducts, Intrahepatic, Biopsy, Cholangiopancreatography, Endoscopic Retrograde, Humans, Bile Duct Neoplasms surgery, Cholangiocarcinoma, Klatskin Tumor
- Abstract
BACKGROUND : Accurate preoperative assessment of the longitudinal extension of perihilar cholangiocarcinoma (PHCC) is essential for treatment planning. Mapping biopsies for PHCC remain challenging owing to technical difficulties and insufficient sample amounts. The aim of this study was to investigate the usefulness of a novel technique for mapping biopsies of PHCC. METHODS : Our novel method focused on a biliary stent delivery system for mapping biopsies. Fifty patients with PHCC undergoing endoscopic transpapillary mapping biopsy using the novel method were reviewed from August 2015 to June 2019. RESULTS : The median number of biopsy samples was six (range 1 - 17), and the rate of adequate sampling was 91.4 % (266 /291). Biopsy from the intrahepatic bile duct was possible in 82.0 % of patients (41 /50), and negative margins were confirmed in the resected specimens from 34 /39 patients who underwent surgery (87.2 %). None of the patients had post-endoscopic retrograde cholangiopancreatography pancreatitis. CONCLUSIONS : With our novel method, accurate assessment of the longitudinal extension of PHCC might be expected with minimal trauma to the duodenal papilla., Competing Interests: The authors declare that they have no conflict of interest., (Thieme. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
6. Hes1 Is Essential in Proliferating Ductal Cell-Mediated Development of Intrahepatic Cholangiocarcinoma.
- Author
-
Matsumori T, Kodama Y, Takai A, Shiokawa M, Nishikawa Y, Matsumoto T, Takeda H, Marui S, Okada H, Hirano T, Kuwada T, Sogabe Y, Kakiuchi N, Tomono T, Mima A, Morita T, Ueda T, Tsuda M, Yamauchi Y, Kuriyama K, Sakuma Y, Ota Y, Maruno T, Uza N, Marusawa H, Kageyama R, Chiba T, and Seno H
- Subjects
- Animals, Bile Duct Neoplasms genetics, Bile Duct Neoplasms metabolism, Cholangiocarcinoma genetics, Cholangiocarcinoma metabolism, Diet adverse effects, Humans, Mice, Knockout, Mice, Transgenic, Proto-Oncogene Proteins p21(ras) genetics, Receptors, Notch metabolism, Bile Duct Neoplasms pathology, Bile Ducts, Intrahepatic pathology, Cholangiocarcinoma pathology, Transcription Factor HES-1 genetics, Transcription Factor HES-1 metabolism
- Abstract
Intrahepatic cholangiocarcinoma (ICC) is frequently driven by aberrant KRAS activation and develops in the liver with chronic inflammation. Although the Notch signaling pathway is critically involved in ICC development, detailed mechanisms of Notch-driven ICC development are still unknown. Here, we use mice whose Notch signaling is genetically engineered to show that the Notch signaling pathway, specifically the Notch/Hes1 axis, plays an essential role in expanding ductular cells in the liver with chronic inflammation or oncogenic Kras activation. Activation of Notch1 enhanced the development of proliferating ductal cells (PDC) in injured livers, while depletion of Hes1 led to suppression. In correlation with PDC expansion, ICC development was also regulated by the Notch/Hes1 axis and suppressed by Hes1 depletion. Lineage-tracing experiments using Epcam
creERT2 mice further confirmed that Hes1 plays a critical role in the induction of PDC and that ICC could originate from PDC. Analysis of human ICC specimens showed PDC in nonneoplastic background tissues, confirming HES1 expression in both PDC and ICC tumor cells. Our findings provide novel direct experimental evidence that Hes1 plays an essential role in the development of ICC via PDC. SIGNIFICANCE: This study contributes to the identification of the cells of origin that initiate ICC and suggests that HES1 may represent a therapeutic target in ICC., (©2020 American Association for Cancer Research.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.